Chandrika Vira is a director in Sterne Kessler’s Trial & Appellate and Biotechnology & Chemical Practice Groups. Chandrika represents clients in complex intellectual property matters in federal district courts, before the International Trade Commission, in contested proceedings before the Patent Trial and Appeal Board, and before the Federal Circuit on appeal.

Chandrika has litigated cases involving a broad range of technologies, including pharmaceuticals, biotechnology products, medical devices, and electrical equipment. In the biotech space, Chandrika recently delivered an eight-figure jury verdict for a client. Additionally, Chandrika has successfully represented and counseled clients in cases involving small-molecule pharmaceuticals under the Hatch-Waxman Act, and biologics and biosimilars under the Biologics Price Competition and Innovation Act (BPCIA). Chandrika has also litigated cases that protect her client’s trademark rights.

Chandrika serves as a strategic advisor to her clients on matters of patent rights as well as trademark, copyright, and false advertising rights. Chandrika regularly writes and speaks on complex patent issues, offering insight and practical advice to her clients. Chandrika is a contributing author of Pre-ANDA Litigation: Strategies and Tactics for Developing a Drug Product and Patent Portfolio, Second Edition, published in 2018 by the American Bar Association.

In addition to her robust practice, Chandrika chairs the firm’s Professional Development Committee and is active in Sterne Kessler’s pro bono practice. Chandrika was recognized by Best Lawyers as “One to Watch in America” in 2024, and by Profiles in Diversity Journal® as a “Women Worth Watching in STEM” in 2023.

Prior to law school, Chandrika worked as a consultant for two technology companies, where she advised companies on implementing technological solutions. While in law school at The George Washington University, Chandrika participated in the Law Students in Court Clinic, where she had the opportunity to represent clients in the Superior Court of the District of Columbia in the Criminal Division. Chandrika received her B.A. in molecular biology from Coe College.

Technical Publications

  • Vira, C. (1998). “Optical and physical properties of bismuth borate glasses related to structure,” Phys. C hem. Glasses, 39(2), 83-6.
  •  Vira, C. (1999). “A Structural analysis of the physical properties of bismuth and lead based glasses.” Phys. C hem. Glasses, 40(6), 326-32.

Representative Matters

  • TwinStrand Biosciences, Inc. and the University of Washington v. Guardant Health, Inc., 21-1126-GBW-SRF (led TwinStrand and the University of Washington to an $83.4 million win before a jury).
  • In re Certain Non-Invasive Aesthetic Body-Contouring Devices, Components Thereof, And Methods Of Using Same, 337-TA-1219 (counsel for Complainant, BTL Industries, Inc. in an ITC investigation pertaining to magnetic body contouring machines)
  • Adapt Pharma Ops.  v. Teva Pharmaceuticals USA (D.N.J.) (counsel for Teva in litigation concerning naloxone, a treatment for opioid overdose)
  • Genentech, Inc. et al. v. Sandoz, Inc. (D.N.J.) (counsel for Sandoz in BPCIA litigation on patents concerning rituximab)
  • Mayne Pharma v. Actavis Elizabeth LLC  (D. Del.) (counsel for Actavis and Teva in Hatch-Waxman litigation on patents concerning doxycycline dosage forms)
  • Sony Corporation v. ARRIS Enterprise LLC (counsel for ARRIS in IPRs concerning broadband technology)
  • Allergan, Inc. v. Teva Pharmaceuticals USA, Inc. et al. (E.D. Tex.) (counsel for Teva in Hatch-Waxman litigation on patents concerning mesalamine)
  • Akorn, Inc. v. Senju Pharmaceuticals Co., Ltd. et al. (counsel for Akorn in an IPR and subsequent appeal on a patent patent concerning difluprednate)
  • Otsuka Pharmaceuticals Co., Ltd. v. Alembic Pharmaceuticals Limited (D.N.J.) (counsel for Alembic in Hatch-Waxman litigation on patents concerning aripiprazole)
  • Salix Pharmaceuticals, Inc. v. Novel Laboratories, Inc. (D. Del.) (counsel for Novel in Hatch-Waxman litigation on patents covering mesalamine)


  • Best Lawyers, “Best Lawyers: Ones to Watch® in America” (2024)
  • Profiles in Diversity Journal®, “Women Worth Watching in STEM” (2023)
  • DCA Live, “Emerging Women Leaders in Law” (2020)
  • Super Lawyers, “Rising Star – Washington, D.C.” (2018-2017)


  • J.D., The George Washington University Law School
  • B.A., Molecular Biology, Coe College


  • District of Columbia
  • New York
  • U.S. Court of Appeals for the Federal Circuit
  • U.S. District Court for the Eastern District of New York
  • U.S. District Court for the Southern District of New York
  • U.S. District Court for the Western District of Michigan
  • United States Patent & Trademark Office


Speaking Engagement 2023 Focus on Pharma Washington, DC, April 14, 2023
Speaking Engagement Redefining Success in the Age of COVID-19: The Bridge to the New Normal Virtual, September 23, 2020
Speaking Engagement Pharma IPR Conference 2020 Mumbai, India, March 4, 2020
Speaking Engagement Women, Diversity & Law: Awareness into Action Summit Philadelphia, PA, December 4, 2019
Speaking Engagement The BPCIA is Turning Ten: What's Next for Biosimilars? Philadelphia, PA, June 3, 2019

Related News & Insights From Chandrika Vira

In the News Delaware Jury: Guardant Willfully Infringed Patents With DNA Sequencing Kits Mealey's Litigation Report: Intellectual Property, pub. 41094 November 16, 2023
Firm Announcements Sterne Kessler Scores $83.4M Federal Jury Verdict for TwinStrand Biosciences, Inc. Sterne, Kessler, Goldstein & Fox November 15, 2023
Press Release Sterne Kessler Notches Multiple Rankings in 2024 “Best Law Firms” List Sterne, Kessler, Goldstein & Fox November 6, 2023
Firm Announcements U.S. District Court Affirms Immigrant Children’s Constitutional Rights Sterne, Kessler, Goldstein & Fox August 29, 2023
In the News DCA Live's 2023 Emerging Women Leaders in Law DCA Live April 5, 2023
Firm Announcements Sterne Kessler Scores Another District Court Patent Win for Client Block Inc. Sterne, Kessler, Goldstein & Fox January 25, 2023
In the News Tidal Escapes Patent Suit Over Music Playlist Tech Law360 January 25, 2023
Firm Announcements Sterne Kessler and D.C. Bar Pro Bono Center Host Sixth Annual Small Business Clinic Sterne, Kessler, Goldstein & Fox June 9, 2022
In the News Skilled in the Art With Scott Graham Law.com May 6, 2022
Firm Announcements District Court Patent Win for Client Block, Inc. Sterne, Kessler, Goldstein & Fox May 3, 2022
In the News Litigator of the Week Runners-Up and Shout Outs Law.com February 18, 2022
In the News Federal Circuit Tosses Naloxone Patents Law Street Media February 11, 2022
In the News Teva Win Invalidating Narcan Patents Upheld by Federal Circuit Bloomberg Law February 10, 2022
In the News Split Fed. Circ. Won't Restore 4 Narcan Patents Law360 February 10, 2022
In the News AbbVie Settles Patent Dispute Over Muscle Stimulation Tech Law360 September 7, 2021
In the News Patent Cases To Watch In The Second Half Of 2020 Law360 July 9, 2020
In the News Teva Invalidates Opiant Patents In Narcan Suit Law360 June 5, 2020
Press Release Sterne Kessler Hosts Virtual Pro Bono Clinic for Small Businesses Sterne, Kessler, Goldstein & Fox P.L.L.C. April 16, 2020
In the News Rival Says Allergan Muscle Toner Not As Strong As Claimed Law360 February 20, 2020
In the News Law Firms: Legal Actions, Decisions Bloomberg Law April 29, 2019
In the News Allergan, Generic Cos. Battle Over Restasis Launch Plans Law360 October 31, 2018
In the News Law360 Names Attys Who Moved Up The Firm Ranks in Q1 fivejars April 28, 2017
Press Release Sterne, Kessler, Goldstein & Fox Elects Five New Directors fivejars January 16, 2017
In the News PTAB Invalidates Claims In Durezol Eye Drops Patent Law360 November 23, 2016
Firm Announcements Sterne Kessler Successfully Represents Alembic Pharmaceuticals Limited in Launching Generic Drug fivejars April 16, 2015 Chandrika Vira, Dennies Varughese, Pharm.D.